A national web-based randomized phase III study of erlotinib [Tarceva] or placebo following concurrent docetaxel, carboplatin, and thoracic radiotherapy in patients with inoperable stage III non-small cell lung cancer (D0410).

Trial Profile

A national web-based randomized phase III study of erlotinib [Tarceva] or placebo following concurrent docetaxel, carboplatin, and thoracic radiotherapy in patients with inoperable stage III non-small cell lung cancer (D0410).

Completed
Phase of Trial: Phase III

Latest Information Update: 19 Nov 2014

At a glance

  • Drugs Erlotinib (Primary) ; Carboplatin; Docetaxel
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 12 Nov 2014 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.
    • 02 Aug 2013 Planned end date changed from 1 Jul 2013 to 1 Sep 2013 as reported by ClinicalTrials.gov.
    • 08 Jan 2013 Planned end date changed from 1 Dec 2012 to 1 Jul 2013 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top